The Weekly Wire
A weekly behavioral-health intelligence briefing: what moved, why it matters, and what to watch next.
Psilocybin, MDMA, ibogaine, ketamine. Trials, regulation, religious exemptions, state programs.
The first peer-reviewed safety and outcomes data from a state-licensed psilocybin program shows strong results: most participants reported benefit, few serious adverse events, and real symptom reductions at three months. The data arrives in the middle of an Oregon Health Authority rulemaking process weighing fee increases that operators say could shut the program down.
Medical science liaisons engage prescribers on the science, not to sell, and the function takes time to build, which is why companies stand it up well ahead of a launch. Compass has kept a field MSL team for about two and a half years and is now hiring a commercial sales force on top of it, while its COMP360 depression NDA is on track to complete in the fourth quarter of 2026, a commercial-readiness signal that lines up with the company's own approval timeline.
Compass Pathways' Redefine Study is a pivotal, FDA-cleared psilocybin trial for PTSD. Resilient's MDMA program is the field's oldest, and it recently resubmitted for approval without new data. The same indication, two companies, two different bets on what regulators will accept.
A theoretical framework built around matrescence and the mother-infant dyad argues the field has waited long enough to study psilocybin in postpartum women. A Johns Hopkins researcher who studies psychedelic adverse events directly names four specific gaps between what the field's leading drug candidate has tested and what a postpartum-specific safety case would require.
Eli Lilly bought its way into psychedelics at scale. AbbVie did the same for a different compound. Compass built a patent fortress instead of buying one. Resilient, once the furthest ahead of anyone, has reportedly tried again without new data. Read together, the companies leading the pharmaceutical side of this sector are running distinctly different strategies, and the differences say more about who wins than who moved first.
Carey Turnbull built Freedom to Operate specifically to force Compass Pathways to withdraw psilocybin patent claims he considers prior art. His own company, Ceruvia Lifesciences, holds patents on BOL-148, a non-hallucinogenic LSD derivative now advancing into a Phase 1/2 trial for cluster headache. Both things are true, and neither cancels the other out.
HLP003 posts a favorable drug-interaction profile specifically enabling use alongside SSRIs. HLP004 gets patients discharged in three hours instead of eight. Neither result addresses whether these compounds work better than existing psychedelics. Both address the two reasons a clinic or an insurer would hesitate to adopt one at scale.
A University of Michigan team scanned brains under psychedelics, sleep, and propofol sedation and found the same network pattern running in exactly opposite directions. The finding speaks directly to a long-running theoretical debate about the neural basis of consciousness, and points toward one side of it. It also matters for a specific, practical reason: sedation is a common comparator in psychedelic mechanism studies, and this data shows it isn't a neutral baseline.
Voyage's topline GAD data is strong on its own terms, a large effect size in an indication with no new drug since 2007. What makes it worth this desk's attention is what it does alongside two prior positive results, and a companion trial explicitly designed around the same functional-unblinding concerns this desk has tracked across the entire psychedelic drug-development field.
Cancer pain, chronic pelvic pain, phantom limb pain, fibromyalgia, migraine: psilocybin trials are now running across a genuinely wide swath of chronic pain medicine. Nearly all of them share the same structural weakness, a pain-scale endpoint that cannot tell whether the drug changed the pain itself or changed how much the pain bothers the patient. That distinction is the entire story.
PIVOT, a new multi-site randomized controlled trial, is the VA's first sponsored efficacy study of psilocybin for treatment-resistant depression in veterans. It launches into an unusually strong proof-of-concept backdrop: an open-label pilot in veterans with severe PTSD, published days earlier, reported no serious adverse events and a 75 percent remission rate.
A retrospective study of 19 patients treated under Switzerland's limited medical-use exemption is among the first real-world psilocybin outcome data generated outside a clinical trial. The response and remission rates land close to what ordinary antidepressants achieve in real-world use, not the dramatic figures the field's early trials reported.
Compass's pivotal trials exclude bipolar disorder outright, stated directly in protocol. A trial now recruiting in Houston enrolls bipolar II patients specifically selected for elevated suicide-risk markers, dosed after coming off their mood stabilizers, though it still excludes patients in active crisis. The prior data on this population is thinner and more mixed than the field's caution suggests.
VCU-1012, a laboratory-designed derivative of the little-used psychedelic quipazine, produced antidepressant-like effects in mice without the gastrointestinal side effects of its parent compound. The result is real and mechanistically interesting. It is not evidence of a psychedelic without the trip, and the distinction matters for how the finding should be read.
The Mystical Experience Questionnaire sits inside nearly every major psychedelic trial as a primary or secondary endpoint. A new review traces its lineage back to a specific, largely unexamined mid-century framework and argues the field inherited a religious category it never should have adopted as science. The proposed fix is more useful than the critique alone: rename the instrument, and use the version its own original architect built later.
The $2.8 billion upfront acquisition gives Lilly a late-stage 5-MeO-DMT program and moves psychedelic drug development from speculative biotech into large-pharma pipeline strategy.
The agreement itself is a coordination document, not a funding commitment or an access pathway. What makes it significant is what it arrived alongside: FDA's final clinical guidance, a September public hearing, and separate ibogaine-specific funding moves from NIDA and ARPA-H, all announced the same day.
Three years after its first draft, FDA has issued final guidance on how to design a psychedelic clinical trial. It does not loosen the bar. It specifies, in granular and sometimes uncomfortable detail, exactly what the agency now expects on blinding, cardiac safety, durability, and drug interactions, the precise questions that have sunk or slowed nearly every program this desk has covered.
The Massachusetts House passed a five-year, three-clinic psilocybin and ibogaine pilot program, tucked into a $561 million economic development bill. Where the state's 2024 legalization ballot measure failed at the polls, this version is narrow, clinical, state-run, and built around a fixed pilot rather than broad personal access, a different model entirely, still needing the Senate and the Governor before it is law.
Psilocybin's clinical trials have repeatedly shown a durable increase in openness after a single supervised dose. A large naturalistic study of German university students set out to see whether that effect shows up in ordinary first-time use. After the statistics were done properly, it mostly disappeared, and what was left wasn't specific to psychedelics at all.
Imperial College London's Centre for Psychedelic Research has published a small, long-running pilot of psilocybin therapy in women with severe, treatment-resistant anorexia nervosa. Eating-disorder symptom scores improved and held for a year in an indication with almost nothing that works. The design, open-label, uncontrolled, in 21 people, sets a hard ceiling on what can be concluded from it.
Compass Pathways' Phase 3 COMP006 trial shows 39 percent of patients on the 25 mg dose maintained response through six months. That number is real. What "maintained" actually means, once you read past the topline, is a post hoc, completers-based analysis in which most patients received an additional intervention along the way. Both things are true at once, and the gap between them is the story.
While psychedelic and cannabinoid drug developers chase headlines, a Texas contract manufacturer has spent the past year and a half filing DEA registration after DEA registration to handle their raw materials, LSD, ibogaine, mescaline, marijuana extract, and more. It is the least glamorous, most necessary layer of the industry, and it is expanding fast.
Canada built two successive federal pathways to get psilocybin and MDMA to patients outside clinical trials. The second one fixed the supply chain the first one lacked, and in doing so made access harder to get, not easier. As U.S. states write their own trigger laws and access frameworks, that trade-off is the one worth studying before it repeats.
A Copenhagen research program is mapping the direct dose-occupancy relationship between LSD and the serotonin 2A receptor in living human brains, the pharmacodynamic binding data that clinical psychedelic trials have mostly assumed rather than measured. With interim results already published and the full program running through 2027, it is the empirical foundation the dosing decisions in Definium's lysergide program could stand to be built on.
Compass Pathways' crystalline-polymorph psilocybin patent has reached granted status as COMP360 moves into rolling FDA submission and the regulatory path clears. Psilocybin itself cannot be patented, so the entire pharmaceutical-psilocybin model rests on owning the exact crystalline form, and patent lawyers still disagree on how much that actually blocks.
Psilocybin for smoking cessation produced some of the most striking pilot results in psychedelic medicine, up to 80 percent abstinence in the first tiny study. It is now in a NIDA-funded multi-site Phase 2, which is both a marker of federal money entering psychedelic-addiction research and the test of whether those eye-popping early effects survive rigor.
A new West Virginia statute is being read as a state prescription pathway for psilocybin that runs ahead of federal scheduling. It is the opposite: a contingent trigger that activates only if the FDA approves and the DEA reschedules a crystalline-polymorph psilocybin first. That structure, and the polymorph language, quietly pick a side in how psilocybin access gets built.
The commercial hope in psychedelics is a drug that keeps the antidepressant effect and drops the hallucination by being selective for the 5-HT2A receptor. The preclinical evidence points the other way: psilocybin's benefit appears to depend on more than 5-HT2A, and if the missing piece is a receptor like 5-HT2B, the one developers normally design around for cardiac safety, two of the field's bets get harder at once.
Definium Therapeutics, the company formerly known as MindMed, reported positive topline Phase 3 results for an orally dissolving form of LSD in major depression. With a second MDD trial, two Phase 3 anxiety trials, and a PTSD study to come, lysergide is now arguably the most advanced classic psychedelic in registrational development. The trial design takes direct aim at the field's biggest methodological problem.
MDMA-assisted therapy is moving beyond PTSD into eating disorders, on the logic that trauma underlies many of these conditions. It is a real research direction, but not a first, and the evidence so far is a secondary analysis and a few early trials. That is the right place to set expectations.
Psilocybin's strongest cancer evidence is in anxiety and depression. A Roswell Park trial extends it to chronic cancer pain and opioid reduction, part of a broader psychedelics-for-pain wave. Treating pain is a different and less-supported claim than treating distress, and the distinction is the whole story.
MDMA cannot be patented; it is a 1912 molecule. So the commercial action has moved to engineered analogues, especially short-acting ones that would shrink the eight-hour session that makes MDMA therapy hard to scale. After the 2024 FDA rejection, the filings, not the trials, are where the next MDMA strategy is taking shape.
On the same day, the New England Journal of Medicine ran one piece on the collision between state-authorized psychedelic programs and federal Schedule I status, and another on informed consent and shared decision-making in psychedelic care. The pairing, and the venue, are the signal: the field's unresolved questions are now jurisdictional and ethical, not pharmacological.
A Yale Phase 1 is testing DMT in major depression with EEG endpoints, part of a psychedelic quietly catching up to psilocybin and MDMA. Its short duration is the structural answer to the session-length problem the rest of the field is spending money to engineer. Whether brevity is enough is the open question.
A new paper quantifies MDMA's concentration-dependent inhibition of CYP2D6, the enzyme that metabolizes several antidepressants common in the PTSD population MDMA therapy is meant to treat. The pharmacokinetic interaction is real, though it is not the only reason concomitant antidepressants get managed.
Compass's pivotal evidence spans North America and Europe and points toward an FDA filing. Australia skipped that route in 2023, letting psychiatrists prescribe psilocybin with no completed pivotal trial. The global path to psychedelic access is fragmenting into models that do not agree on what evidence is required first.
HLP003, Helus Pharma's deuterated psilocin analog engineered for a shorter trip, is now months from its first Phase 3 readout in major depression. It does not differ from Compass on biology. It differs on session length, dosing, and the breadth of the population it targets.
A new PNAS paper reports that psychedelics scramble hierarchical cortical propagation in the default mode network across both humans and mice. The cross-species match strengthens the case that this disruption is a real circuit mechanism. It says nothing yet about whether the disruption helps anyone.
A five-year NIDA award sends federal researchers into Oregon's legal psilocybin program to track safety and substance-use outcomes in thousands of real clients. It is the first dataset built from psychedelic use outside controlled-trial conditions, and that is the point.
Compass hit both pivotal trials, has a rolling NDA underway, and holds a priority voucher that could compress review to one or two months. The regulatory path is now the fast part. The durability and effect-size data are the part still being written.
A map of the surviving programs after the August 2024 MDMA rejection and the April 2026 voucher decisions. The field is narrower than press coverage suggests, and the survivors are concentrated in a small number of well-funded sponsors with overlapping bets on the same handful of molecules.
| Program | Sponsor | Phase | Status |
|---|---|---|---|
| DT120 (lysergide ODT) Generalized anxiety disorder | Definium Therapeutics (formerly MindMed) | Phase 3 | Phase 3 positive (Voyage); second pivotal (Panorama) reads out Sept 2026 |
| BPL-003 (intranasal mebufotenin) Treatment-resistant depression | AtaiBeckley | Phase 3 | Phase 3 initiated; Lilly acquisition announced |
| COMP360 psilocybin Treatment-resistant depression | Compass Pathways | Phase 3 | Phase 3 complete; rolling NDA underway |
| HLP003 (deuterated psilocin) Major depressive disorder | Helus Pharma (formerly Cybin) | Phase 3 | Breakthrough designation; Phase 3 APPROACH topline expected 2H 2026 |
| DT120 (lysergide ODT) Major depressive disorder | Definium Therapeutics (formerly MindMed) | Phase 3 | Phase 3 positive; second trial enrolling |